Maropitant-d3

CAT: 0804-HY-10053S-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10053S-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Maropitant-d3 is the deuterium labeled Maropitant. Maropitant is a selective and orally active neurokinin (NK1) receptor antagonist. Maropitant acts by blocking the binding of substance P within the emetic center and the chemoreceptor trigger zone (CRTZ) . Maropitant is highly effective in preventing vomiting[1][2].
CAS Number
[2124295-52-7]
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Neurokinin Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling; Others
Field of Research
Neurological Disease; Endocrinology
Solubility
10 mM in DMSO
Smiles
CC(C)(C)C1=CC=C(OC([2H])([2H])[2H])C(CN[C@@H]2[C@H](C(C3=CC=CC=C3)C4=CC=CC=C4)N5CCC2CC5)=C1
Molecular Formula
C32H37D3N2O
Molecular Weight
471.69
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg. 2013 Jan;40 (1) :28-34.|[3]Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther. 2012 Nov 20.|[4]Alvillar BM, Boscan P, Mama KR, et al. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012 Mar;39 (2) :201-5.|[5]Ramsey DS, Kincaid K, Watkins JA et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008 Dec;31 (6) :538-43. doi: 10.1111/j.1365-2885.2008.00992.x.|[6]Benchaoui HA, Cox SR, Schneider RP et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007 Aug;30 (4) :336-44.|[7]Maropitant
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10053S1-01Maropitant-13C, d3
HY-10053-01Maropitant
HY-10053BMaropitant (citrate)
HY-10053R-01Maropitant (Standard)
HY-10053AMaropitant (citrate hydrate)
HY-15398S3-01Vitamin D3-d3
HY-132348S1Granisetron-d3 (1-methyl-d3)
HY-150954SL-Methionine-d3 (S-methyl-d3) Methyl-d3-sulfonium Chloride
HY-W758392(±) -Ipratropium-d3 Bromide (N-methyl-d3)
HY-B1213AS-01Trimipramine-d3 (N-methyl-d3) (maleate)

Alternative Products

CatalogName
TRC-M197302-100MGMaropitant-d3
RM-M101101-01Maropitant-13C-D3
MBS3610634-01Maropitant
BUP18859-01Maropitant citrate
A21473-100Maropitant 100mg
A21473-10Maropitant 10mg
A21473-2Maropitant 2mg
A21473-5Maropitant 5mg
A21473-200Maropitant 200mg
A21473-25Maropitant 25mg

Popular Products